16,942 Shares in PAREXEL International Co. (PRXL) Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. purchased a new position in shares of PAREXEL International Co. (NASDAQ:PRXL) during the first quarter, according to its most recent filing with the SEC. The fund purchased 16,942 shares of the medical research company’s stock, valued at approximately $1,069,000. PAREXEL International accounts for about 0.4% of Fox Run Management L.L.C.’s portfolio, making the stock its 15th largest position.

Several other large investors have also recently bought and sold shares of PRXL. Hsbc Holdings PLC boosted its stake in shares of PAREXEL International by 0.8% in the third quarter. Hsbc Holdings PLC now owns 6,253 shares of the medical research company’s stock valued at $434,000 after buying an additional 51 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in PAREXEL International by 0.8% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 7,886 shares of the medical research company’s stock valued at $518,000 after buying an additional 63 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in PAREXEL International by 1.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,552 shares of the medical research company’s stock valued at $431,000 after buying an additional 84 shares during the last quarter. Isthmus Partners LLC increased its position in PAREXEL International by 1.2% in the third quarter. Isthmus Partners LLC now owns 11,305 shares of the medical research company’s stock valued at $763,000 after buying an additional 131 shares during the last quarter. Finally, Pacer Advisors Inc. increased its position in PAREXEL International by 3.4% in the third quarter. Pacer Advisors Inc. now owns 4,491 shares of the medical research company’s stock valued at $312,000 after buying an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 91.44% of the company’s stock.

Institutional Ownership by Quarter for PAREXEL International (NASDAQ:PRXL)

Shares of PAREXEL International Co. (NASDAQ:PRXL) traded up 1.85% during midday trading on Tuesday, reaching $79.35. 1,897,858 shares of the company were exchanged. The firm has a 50-day moving average of $65.12 and a 200 day moving average of $64.23. The firm has a market capitalization of $4.03 billion, a P/E ratio of 34.88 and a beta of 0.82. PAREXEL International Co. has a 52 week low of $51.16 and a 52 week high of $80.20.

PAREXEL International (NASDAQ:PRXL) last released its quarterly earnings results on Wednesday, May 3rd. The medical research company reported $0.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. The firm had revenue of $529.30 million during the quarter, compared to analysts’ expectations of $529.38 million. PAREXEL International had a return on equity of 29.92% and a net margin of 6.34%. PAREXEL International’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.89 EPS. On average, equities research analysts expect that PAREXEL International Co. will post $3.24 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “16,942 Shares in PAREXEL International Co. (PRXL) Acquired by Fox Run Management L.L.C.” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.com-unik.info/2017/05/16/fox-run-management-l-l-c-acquires-new-position-in-parexel-international-co-prxl-updated-updated-updated.html.

PRXL has been the topic of several recent analyst reports. Evercore ISI upgraded shares of PAREXEL International from an “in-line” rating to an “outperform” rating and set a $85.00 price objective on the stock in a research report on Monday. Zacks Investment Research upgraded shares of PAREXEL International from a “hold” rating to a “buy” rating and set a $80.00 price objective on the stock in a research report on Friday, January 20th. Raymond James Financial, Inc. cut shares of PAREXEL International from a “market perform” rating to an “underperform” rating in a research note on Thursday, February 2nd. Jefferies Group LLC raised their target price on shares of PAREXEL International from $64.00 to $67.00 and gave the company a “hold” rating in a research note on Tuesday, January 24th. Finally, Deutsche Bank AG cut shares of PAREXEL International from a “hold” rating to a “sell” rating and cut their target price for the company from $66.00 to $53.00 in a research note on Friday, February 3rd. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the stock. PAREXEL International currently has an average rating of “Hold” and an average price target of $70.30.

In other PAREXEL International news, SVP Sybrand Pretorius sold 8,050 shares of the company’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $65.12, for a total value of $524,216.00. Following the transaction, the senior vice president now directly owns 9,950 shares of the company’s stock, valued at approximately $647,944. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.90% of the stock is owned by corporate insiders.

About PAREXEL International

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

5 Day Chart for NASDAQ:PRXL

What are top analysts saying about PAREXEL International Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PAREXEL International Co. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit